Clinical Trials Logo
  1. Home
  2. Alport Syndrome
  3. NCT05133050

Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants

Alport Syndrome Clinical Trial

Official title:
Safety and Efficacy of Early Angiotensin-converting Enzyme Inhibition in Patients With Alport Syndrome Carrying Pathogenic Heterozygous COL4A3,COL4A4 or COL4A5 Mutations

Clinical Trial Summary

Alport syndrome (AS) is the second most common monogenic cause of end-stage renal failure (ESRF). AS is caused by variants in the COL4A3, COL4A4, and COL4A5 genes, which encode for the a3, a4, and a5 chains of type IV collagen. This trial is a prospective, randomized, controlled and multicenter trial. Mainly to assess the safety and efficacy of ramipril in Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05133050
Study type Interventional
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact Gengru Jiang
Phone +86-13917983703
Email jianggeng-ru@hotmail.com
Status Not yet recruiting
Phase N/A
Start date January 1, 2022
Completion date December 31, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01602835 - Human Urine Sample Collection for Alport Nephropathy Biomarker Studies N/A
Completed NCT01696253 - Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Recruiting NCT00481130 - Alport Syndrome Treatments and Outcomes Registry
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT05448755 - A Study of ELX-02 in Patients With Alport Syndrome Phase 2
Recruiting NCT06274489 - A Study to Evaluate Setanaxib in Patients With Alport Syndrome Phase 1/Phase 2
Terminated NCT02855268 - Study of Lademirsen (SAR339375) in Patients With Alport Syndrome Phase 2
Recruiting NCT06226896 - Effects of Dapagliflozin on Progression of Alport Syndrome
Recruiting NCT05927467 - Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Terminated NCT03749447 - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Phase 3
Completed NCT03019185 - A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Phase 2/Phase 3
Completed NCT01705132 - Urinary Biomarkers of the Progression of Alport Kidney Disease N/A
Recruiting NCT05267262 - Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Phase 2
Completed NCT00622544 - A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Recruiting NCT02378805 - European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Not yet recruiting NCT05655728 - Treatment With Metformin in Chinese Children With Alport Syndrome Phase 4
Completed NCT00309257 - Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome Phase 2
Recruiting NCT04947813 - Genotype-Phenotype Correlations in Patients With Alport Syndrome
Active, not recruiting NCT04573920 - Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2